Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL3776314

N.Oc1ccc(-c2nc3cncc4c2nc34)cc1O

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 1/20 0.41
QDPR P09417 1/20 0.39
PIK3CG P48736 3/20 0.38
APP P05067 2/20 0.38
MAPT P10636 2/20 0.38
POLB P06746 2/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
HSP90AA1 P07900 1/20 0.38
GAA P10253 1/20 0.38
PKM P14618 1/20 0.38
HTT P42858 1/20 0.38
GRK6 P43250 1/20 0.38
SNCA P37840 3/20 0.36
ALOX5 P09917 4/20 0.35
CSNK2A2 P19784 1/20 0.34
CSNK2B P67870 1/20 0.34
GUSB P08236 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13019162 0.76 PIK3CG (0.51) JAK3QDPRPIK3CGAPPMAPT
Hydrochloric Acid SCHEMBL3738570 0.75 PIK3CG (0.50) JAK3QDPRPIK3CGAPPMAPT
SCHEMBL13019022 0.70 PIK3CG (0.45) JAK3PIK3CGMAPTPOLBKDM4E
SCHEMBL28177268 0.65 APP (0.67) QDPRAPPSNCAALOX5
SCHEMBL13019202 0.61 PIK3CG (0.64) JAK3QDPRPIK3CGAPPMAPT
Hydrochloric Acid SCHEMBL4361282 0.61 MAPK14 (0.51) JAK3QDPRPIK3CGAPPMAPT
SCHEMBL338028 0.60 APP (1.00) QDPRAPPMAPTSNCAALOX5
Hydrochloric Acid SCHEMBL3737551 0.60 PIK3CG (0.62) JAK3QDPRPIK3CGAPPMAPT
SCHEMBL7612535 0.60 APP (0.65) JAK3QDPRAPPMAPTPOLB
SCHEMBL13019198 0.59 PIK3CG (0.54) JAK3QDPRPIK3CGAPPMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2039683-B1 Vasculostatic agents and methods of use thereof TARGEGEN INC (US) 2012-12-19 EP disclosed
US-20100330030-A1 Vasculostatic Agents and Methods of Use Thereof TARGEGEN, INC. (US) 2010-12-30 US disclosed
EP-2039683-A2 Vasculostatic agents and methods of use thereof Targegen, Inc. (US) 2009-03-25 EP disclosed
US-7208493-B2 Vasculostatic agents and methods of use thereof TARGEGEN, INC. (US) 2007-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100330030-A1 Vasculostatic Agents and Methods of Use Thereof RBP1, RBP4, VCAM1 JAK3 2288/4885QDPR 1516/4885PIK3CG 2378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.